THALES/TELIT-CINTERION
27.2.2024 09:01:30 CET | Business Wire | Press release
Telit Cinterion IoT modules featuring Thales Instant Connect can be remotely activated for cellular connectivity at the time of device installation or during in-field operation. This streamlines IoT deployments as it simplifies supply chain, device installation and maintenance, helping to keep IoT devices connected anywhere, and at all times. Aidon, a leader in smart metering solutions, is the first to benefit from this partnership and solution, deploying IoT modules and initial connectivity from a single vendor, Telit Cinterion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240227054738/en/
credit > sergray
By integrating Thales technology into Telit Cinterion modules, enterprises can enjoy instant out-of-the-box connectivity activation irrespective of the grid of available mobile networks. The collaboration between the two companies on this innovative solution enables them to get their IoT connected products in the market quickly, allowing them to reap the benefits of digital transformation that is at the core of the IoT promise.
The way the solution works is that, at the end of device production or when it is deployed in the field, the Telit Cinterion module uses the initial connectivity provided by Thales Instant Connect, to download the target local connectivity from the network operators selected by the IoT service provider. This allows device manufacturers and service providers to postpone selecting a connectivity provider until after the device is manufactured and throughout the deployment process. It can also be used during in-field operation, enabling deployed devices to stay connected throughout unexpected cellular network outages. This flexibility is particularly beneficial in situations where the devices are deployed across different regions or countries, as it allows for seamless integration with local network operators.
“Helping our enterprise customers to quickly launch and monetize IoT is our mission at Telit Cinterion. Adding the Thales eSIM to our modules in combination with our SIM provisioning and global MVNO services to streamline the final connectivity provider selection is a game changer in the industry. This powerful solution delivers unparalleled adaptability to changing circumstances and simplifies supply chain and logistics because it is based on a single eSIM with Thales Instant Connect, which can be shipped anywhere in the world,” said Manish Watwani, Chief Marketing and Product Officer at Telit Cinterion.
“The IoT eSIM solution is an important innovation, ensuring production flexibility and connectivity of our smart meters, even in rural areas, and all without the need for physical handling of SIMs. The solution provides a true operator selection and provisioning at any stage of the product lifetime. It is improving our ability to get smart meters connected, stay connected and adapt to new metering as-a-service business models,” said Petri Ounila, Director, IoT Devices, Aidon.
“Thales aims to support IoT adopters and streamline device deployment with our eSIM with initial connectivity via Thales Instant Connect service. This simplifies and accelerates large scale IoT deployments for device makers, benefiting all stakeholders in the value chain. Thales is pleased to work with Telit Cinterion to support its success in cellular connectivity and speed up device deployment,” said Guillaume Lafaix, Senior Vice President Mobile Connectivity Solutions at Thales.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organizations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfill their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 77,0001 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.
_______________________________
1 Excluding Transport business, which is being divested
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227054738/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom